NO169638C - Formuleringsblanding med stabiliserende virkning paa alfa-interferon - Google Patents

Formuleringsblanding med stabiliserende virkning paa alfa-interferon

Info

Publication number
NO169638C
NO169638C NO870441A NO870441A NO169638C NO 169638 C NO169638 C NO 169638C NO 870441 A NO870441 A NO 870441A NO 870441 A NO870441 A NO 870441A NO 169638 C NO169638 C NO 169638C
Authority
NO
Norway
Prior art keywords
active ingredient
stabilizing effect
formulation mixture
alfa interferon
ifn alpha
Prior art date
Application number
NO870441A
Other languages
English (en)
Norwegian (no)
Other versions
NO870441D0 (no
NO870441L (no
NO169638B (no
Inventor
Helmut Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO870441D0 publication Critical patent/NO870441D0/no
Publication of NO870441L publication Critical patent/NO870441L/no
Publication of NO169638B publication Critical patent/NO169638B/no
Publication of NO169638C publication Critical patent/NO169638C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO870441A 1986-02-05 1987-02-04 Formuleringsblanding med stabiliserende virkning paa alfa-interferon NO169638C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (de) 1986-02-05 1986-02-05 Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha

Publications (4)

Publication Number Publication Date
NO870441D0 NO870441D0 (no) 1987-02-04
NO870441L NO870441L (no) 1987-08-06
NO169638B NO169638B (no) 1992-04-13
NO169638C true NO169638C (no) 1992-07-22

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO870441A NO169638C (no) 1986-02-05 1987-02-04 Formuleringsblanding med stabiliserende virkning paa alfa-interferon

Country Status (20)

Country Link
EP (1) EP0231816B1 (da)
JP (1) JPS62209024A (da)
KR (1) KR870007698A (da)
AT (1) ATE63823T1 (da)
AU (1) AU601712B2 (da)
CA (1) CA1295242C (da)
DD (1) DD284602A5 (da)
DE (2) DE3603444A1 (da)
DK (1) DK164202C (da)
ES (1) ES2028796T3 (da)
FI (1) FI86144C (da)
GR (1) GR3002270T3 (da)
HU (1) HU196560B (da)
IE (1) IE59697B1 (da)
IL (1) IL81472A0 (da)
NO (1) NO169638C (da)
NZ (1) NZ219169A (da)
PH (1) PH24377A (da)
PT (1) PT84243B (da)
ZA (1) ZA87793B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
DE3803312A1 (de) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Verwendung eines interferonenthaltenden gels
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
EP0374257B1 (en) * 1988-05-06 1994-08-31 Toray Industries, Inc. STABLE INTERFERON $g(b) COMPOSITION
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
EP0607275A4 (en) * 1991-10-11 1995-02-22 Mark Cedric Gillies TREATMENT OF OPHTHALMIC FIBROSE WITH ALPHA INTERFERON.
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (fi) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001243431B2 (en) * 2000-03-07 2006-05-25 Rush University Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
CN1582167A (zh) * 2001-11-02 2005-02-16 积水化学工业株式会社 细胞因子诱导材料和细胞因子诱导装置
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
SG176254A1 (en) * 2009-05-29 2011-12-29 Filligent Ltd Composition for use in decreasing the transmission of human pathogens
RU2431489C1 (ru) * 2010-05-25 2011-10-20 Федеральное государственное учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦРР Росмедтехнологий") Способ лечения хронических воспалительных заболеваний толстого кишечника
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
JP6081156B2 (ja) * 2012-11-15 2017-02-15 アルケア株式会社 ハイドロゲル
DE102012222365A1 (de) 2012-12-05 2014-06-05 Aesculap Ag Zusammensetzung zur Anwendung bei der Prophylaxe von post-chirurgischen Adhäsionen
WO2014199373A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc- macrophage activating factor and uses thereof
MX390707B (es) 2017-01-31 2025-03-21 Kimberly Clark Co Composición antibacteriana que incluye un éster del ácido benzoico y métodos de inhibición del crecimiento bacteriano mediante el uso de la misma.
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (ja) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト 製薬学的組成物
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS60260523A (ja) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd インタ−フエロンの凍結乾燥医薬組成物

Also Published As

Publication number Publication date
KR870007698A (ko) 1987-09-21
IE59697B1 (en) 1994-03-23
DK58387A (da) 1987-08-06
AU601712B2 (en) 1990-09-20
EP0231816A2 (de) 1987-08-12
NO870441D0 (no) 1987-02-04
NO870441L (no) 1987-08-06
DK164202C (da) 1992-10-19
JPS62209024A (ja) 1987-09-14
HU196560B (en) 1988-12-28
IE870295L (en) 1987-08-05
FI86144C (fi) 1992-07-27
DD284602A5 (de) 1990-11-21
PH24377A (en) 1990-06-13
AU6829287A (en) 1987-08-06
PT84243A (de) 1987-03-01
NZ219169A (en) 1990-04-26
DE3603444A1 (de) 1987-08-06
FI86144B (fi) 1992-04-15
IL81472A0 (en) 1987-09-16
CA1295242C (en) 1992-02-04
FI870457A0 (fi) 1987-02-03
FI870457L (fi) 1987-08-06
EP0231816A3 (en) 1987-09-23
DK58387D0 (da) 1987-02-04
EP0231816B1 (de) 1991-05-29
GR3002270T3 (en) 1992-12-30
DK164202B (da) 1992-05-25
ES2028796T3 (es) 1992-07-16
NO169638B (no) 1992-04-13
HUT43494A (en) 1987-11-30
ZA87793B (en) 1988-10-26
ATE63823T1 (de) 1991-06-15
DE3770280D1 (de) 1991-07-04
PT84243B (pt) 1989-09-14

Similar Documents

Publication Publication Date Title
NO870441L (no) Farmasoeytiske preparatformer for stabilisering av alfa-interferon.
DK203787D0 (da) Praeparat til nasal administrering
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
SE8505112D0 (sv) Novel pharmacological compounds
ATE180969T1 (de) Pharmazeutische zusammensetzungen enthaltend urodeoxycholicsäure
DK305087A (da) Buprenorphinholdigt farmaceutisk suppositorium
DK516288D0 (da) Stabilisering af terapeutisk aktive proteiner i farmaceutiske praeparater
DK396286A (da) Injicerbar formulering med forsinket frigivelse af den aktive bestanddel
DE3777769D1 (de) Pharmazeutische produkte.
NO863027L (no) Peptidpreparater med kontinuerlig avgivelse.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
DE68906572D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
ATE30417T1 (de) N-substituierte 1-(4'-alkylthiophenyl)-2-amino1,3-propanediol-derivate.
ES2016052A6 (es) Procedimiento para preparar derivados de adenosinmonofosfonato (amp) ciclico y de guanosinmonofosfonato (gmp) ciclico.
DK0578535T3 (da) Hidtil ukendt peptid-derivater, der er aktive i celleadhæsionsprocesser, fremgangsmåde til deres fremstilling samt farmaceutiske sammensætninger indeholdende derivarerne
KR910009280A (ko) 원발성 흉막암 치료용 제약 조성물의 제조에 있어서 감마 인터페론 활성을 갖는 폴리펩티드의 용도
IT1216103B (it) Peptidi ad attivita' farmaceutica.
IT8723007A0 (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle